May 1985

Nifedipine in Antihypertensive Therapy

Author Affiliations

Tel-Hashomer, Israel

Arch Intern Med. 1985;145(5):953-954. doi:10.1001/archinte.1985.00360050223049

To the Editor.  —We read with interest the article by Evans et al1 in the May 1984 Archives. Their results are similar to ours in demonstrating nifedipine efficacy as a substitute for hydralazine and captopril in combination antihypertensive therapy.2 Recently, McAreavey et al3 suggested hydralazine as the best third-line drug. Nifedipine was shown by Evans et al, Ueda and Marakami,4 and us2 to be a successful substitute for hydralazine in about 100 patients.A well-controlled study5 showed that nifedipine's hypotensive effect compared favorably with that of hydralazine shown in a similar study.6In summary, we feel that nifedipine should be considered as a most valuable vasodilator in combination antihypertensive therapy due to the efficacy, lower incidence of side effects (especially in the long-acting tablet preparation), and the protection from ischemic symptoms and events so prevalent in severely hypertensive patients.

First Page Preview View Large
First page PDF preview
First page PDF preview